Piramal Pharma Ltd Share Price Today

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 1.4% at ₹0.14/Share	16-Jul-2025	16-Jul-2025

Mutual Fund Holder	Aug 26 Shares held	Sep 26 Shares held
HDFC Flexi Cap Fund - Growth	7.64 Cr	7.18 Cr (6.02%)
Nippon India Pharma Fund - Growth	99.37 Lac	99.37 Lac no change
Bandhan Small Cap Fund - Regular Plan - Growth	98.97 Lac	98.97 Lac no change
Franklin India Opportunities Fund - Growth	61.54 Lac	61.54 Lac no change
Bajaj Finserv Flexi Cap Fund - Regular Plan - Growth	60.21 Lac	60.21 Lac no change

Palak Jain

28 Oct • 9:15 PM · SEBI-Registered Analyst

Piramal Pharma Returns To Profit With Strong Revenue Growth

PPLPHARMA

a has delivered a turnaround worth paying attention to. For Q2 FY27, the company reported a consolidated net profit of around ₹5.6 crore, compared with a loss of ₹99.2 crore in the same quarter last year. Revenue grew 28% to ₹2,617 crore, while EBITDA increased 72% to ₹385 crore. But the bigger development came with its full-year outlook. Piramal Pharma raised its FY27 revenue growth guidance to 19–20%, following strong first-half performance. Its contract development and manufacturing business (CDMO), which helps pharmaceutical companies develop and manufacture medicines, grew 36% during the first half. This business is particularly interesting because pharmaceutical companies often outsource specialised manufacturing and development work rather than building all the capabilities themselves. Piramal is also seeing growth across its complex hospital generics and consumer healthcare businesses, making the latest performance broader than a single-segment recovery. However, there’s still something to monitor: the company remains loss-making on a first-half net-profit basis, despite returning to quarterly profitability. Sustaining margins and converting growth into consistent earnings will be important. For me, the key question is whether this quarter marks the beginning of a sustained earnings recovery or simply a strong period in a longer turnaround. The next few quarters should tell us more.

Umang Bhutada

28 Oct • 2:48 PM · SEBI-Registered Analyst

EBITDA jumps 72%, but net profit remains the key concern

Piramal Pharma Limited (

PPLPHARMA

) reported strong revenue and operating-profit growth in Q2 FY27, and raised its full-year revenue growth outlook. However, the improvement in operating performance has not yet translated into positive consolidated net profit. Key Q2 FY27 numbers Revenue from operations: ₹2,617 crore, up 28% year-on-year. EBITDA: ₹385 crore, up 72%. EBITDA margin: approximately 14.7%, compared with 11.0% a year earlier. Consolidated net profit after tax: approximately ₹5 crore, versus a loss of ₹99 crore in the year-ago quarter. FY27 revenue growth outlook raised to 19%–20%. Why this matters The improvement in EBITDA indicates better operating leverage and cost discipline. The company’s contract development and manufacturing organisation (CDMO) business was a major growth driver. Yet the small reported net profit highlights the impact of depreciation, interest costs and taxes. What to monitor next CDMO order inflows and capacity utilisation. Whether EBITDA margins remain above year-ago levels. Conversion of operating earnings into net profit and cash flow. Execution against the upgraded FY27 growth outlook. My analytical view The operating trend is encouraging, but investors should not confuse EBITDA growth with net-profit growth. Consistent execution and stronger bottom-line conversion will be important to establish a sustainable earnings recovery. Risk: Regulatory issues, customer concentration, product-quality risks and high operating or financing costs could affect performance. SEBI RA Disclaimer: Umang Rajesh Bhutada is a SEBI-registered Research Analyst (INH000023001). This content is for educational and informational purposes only and is not investment advice. Securities investments are subject to market risks. Please consult a qualified financial professional before making investment decisions.

Akshay Patel

28 Oct • 8:58 AM · SEBI-Registered Analyst

Piramal Pharma Q2 revenue rises 28.43% to ₹2,620 crore

Piramal Pharma Limited (NSE: PPLPHARMA)

PPLPHARMA

reported Q2 revenue of ₹2,620 crore. That is up about 28.43% from ₹2,040 crore in the same quarter last year. The growth rate is my calculation from the two reported figures. This is a top-line update only. No margin or profit data is included. What happened: The board met on October 27, 2026 to approve the results. An investor call followed on October 28, 2026. Revenue rose ₹580 crore year on year. Why it matters: Growth of this size points to higher volumes and steady demand across the contract development and generic pharma operations. Global outsourcing demand for CDMO and specialty pharma work gives the business a supportive backdrop. My view: Revenue growth alone does not tell us earnings quality. A 28% jump can come from volumes, pricing, new contracts or currency. The data here does not split these. If margins held while revenue grew, the growth is worth more. If API input costs ate into margins, the headline flatters the business. So I treat this as a strong first step, not a finished case. What I am watching: margin comments from the October 28 investor call, API costs and rupee moves, and quality audit outcomes at key global manufacturing sites. A second quarter of similar growth would strengthen the case. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.

CA Sumit Mangla

21 Oct • 5:43 PM · SEBI-Registered Analyst

Jubilant Pharmova assigned IND AA+/Stable to ₹1,400 Cr NCDs.

JUBLPHARMA

Jubilant Pharmova Limited (JUBLPHARMA) has received a credit rating assignment from India Ratings and Research Pvt Ltd. The rating is for proposed non-convertible debentures amounting to ₹1,400 crore. The instrument is Proposed Non-Convertible Debentures of ₹1,400 crore. The assigned rating is IND AA+/Stable. The rating action is Assigned. The key trigger is the assignment of an IND AA+/Stable rating for the proposed ₹1,400 crore NCD issuance, which supports the company’s funding plans without equity dilution. This reflects a favourable view of its credit profile in the specialty pharmaceuticals and CDMO space. Peers such as Syngene International, Piramal Pharma, and Divi’s Laboratories may face comparison on balance-sheet strength and debt-raising capacity. Near-term prices could see a mild positive reaction on the rating assignment and funding visibility. Risks include the final terms of the NCD issuance or any subsequent pressure on leverage metrics. Competitors listed: Syngene International, Piramal Pharma, Divi’s Laboratories.

Amit Malviya

23 Sep • 10:48 AM · SEBI-Registered Analyst

Wockhardt Pharma (WOCKPHARMA) has reported strong Q1 FY27

!WOCKPHARMA Wockhardt Pharma has reported results with a net profit of ₹107 crore, marking a sharp turnaround from losses last year. The company is focusing on biotech expansion, insulin launches, and has shareholder approval for a ₹3,000 crore capital raise. 📊 Wockhardt Pharma Latest News (September 2026) 🔑 Financial Highlights Revenue (Q1 FY27): ₹929 crore QoQ: Down 3.7% from ₹965 crore YoY: Up 25.9% from ₹738 crore Operating Profit: ₹192 crore YoY growth: 868% Net Profit (PAT): ₹107 crore YoY growth: 199% EBITDA Margin: Expanded to 20.2% EPS: ₹6.55 (vs. ₹10.23 in Mar 2026) 📈 Stock Market Performance NSE Price (22 Sept 2026): ₹2,212 BSE Price (22 Sept 2026): ₹2,217.60 1-Year Gain: +48% Promoter Holding: 49.1% Valuation: P/E ratio at 86.7, reflecting high investor expectations 🚀 Strategic Developments Capital Raise: Shareholder approval for up to ₹3,000 crore via QIP/public offerings. Biotech Focus: Expanding into insulin analogs and novel drugs. Pipeline: Targeting 50% of revenue from novel drugs within 5 years. Key Drug: Antibiotic Zaynich approved by CDSCO, with US launch expected by year-end. Peak Sales Target: $1.5 billion from Zaynich 📰 Industry Context Pharma Rally: Nifty Pharma index up 2% recently, with peers like Laurus Labs and Piramal Pharma also surging. Wockhardt Stock Movement: Up 75% in one month, hitting all-time highs on regulatory approvals. 📌 Key Takeaways for Investors Strong turnaround: From losses to consistent profitability. High growth potential: Driven by biotech and novel drug launches. Risks: Elevated valuation makes the stock sensitive to execution delays in insulin launches or margin pressures. Opportunity: Strategic capital raise and global expansion could fuel long-term growth.

Vineet Chawla

10 Sep • 8:40 PM · SEBI-Registered Analyst

trading near its 52 week breakout level.

trading near its 52 week breakout level. !PPLPHARMA is trading near its 52 week breakout level. • The 52-week breakout strategy focuses on stocks that cross their highest price of the past one year, often indicating strong bullish momentum and renewed buying interest. • When a stock moves above its 52-week high, it enters a zone with no previous resistance, which can support further upward movement if momentum continues. • Traders usually look for higher trading volumes, strong closing prices, and the stock trading above key moving averages to confirm the breakout. • Proper risk management is essential. A stop loss slightly below the breakout level helps limit downside risk while allowing traders to participate in potential trending moves. Disclaimer: Investments in securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. The above analysis is for educational and learning purpose. SEBI Registered Research Analyst: Vineet Ashwinikumar Chawla: INH000008190, BSE Enlistment No: 5433

Piramal Pharma Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Piramal Pharma Ltd. 👋

Expert Opinions

News & Events

Frequently Asked Questions

What is the share price of Piramal Pharma Ltd.?

What is the market cap of Piramal Pharma Ltd.?

Should I buy Piramal Pharma Ltd. stock now?

What is the 52 week high and low of Piramal Pharma Ltd.?

Is the Piramal Pharma Ltd. stock good to buy?

Is Piramal Pharma Ltd. a good buy for the long term?

Is Piramal Pharma Ltd. overvalued or undervalued?

What is the PE and PB ratio of Piramal Pharma Ltd.?